Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IDAMYCIN vs CERUBIDINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Idarubicin is an anthracycline antineoplastic agent that intercalates with DNA and inhibits topoisomerase II, leading to inhibition of DNA replication and transcription, and ultimately cell death. It also generates free radicals and induces apoptosis.
Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II and preventing DNA replication and transcription, leading to cell death.
Treatment of acute myeloid leukemia (AML) in adults, including induction therapy in combination with other agents,Treatment of acute lymphoblastic leukemia (ALL) (off-label)
Acute myeloid leukemia,Acute lymphoblastic leukemia,Chronic myeloid leukemia in blast crisis,Kaposi's sarcoma (off-label)
12 mg/m² IV daily for 3 days (acute myeloid leukemia) or 12 mg/m² IV daily for 3 days (acute lymphoblastic leukemia); maximum cumulative dose 600 mg/m².
45–60 mg/m² IV on days 1–3 every 21–28 days, or 30–60 mg/m² IV daily for 3 days every 3 weeks.
Terminal elimination half-life: 20-30 hours (mean ~22 hours). Prolonged in severe hepatic impairment (up to 40 hours) and may be extended in patients with renal impairment due to accumulation of active metabolite idarubicinol (half-life > 60 hours).
Triphasic elimination: initial half-life 30 min (distribution), intermediate 3-5 hours (metabolism), terminal half-life 20-30 hours (slow elimination from tissues). Clinically relevant for scheduling and myelosuppression monitoring.
Idarubicin is extensively metabolized in the liver to its active metabolite idarubicinol, which has similar antineoplastic activity. The primary enzyme involved is aldo-keto reductase. Idarubicin and idarubicinol are eliminated via biliary excretion and renal excretion.
Primarily hepatic metabolism via aldo-keto reductases to daunorubicinol (active metabolite), and further via CYP2D6 and carbonyl reductases.
Primarily hepatic metabolism; biliary excretion of metabolites accounts for ~50% of total elimination. Renal excretion of unchanged drug is minimal (<10%). Approximately 30-40% of the dose is recovered in urine as metabolites. Fecal elimination of metabolites accounts for ~50%.
Primarily hepatic metabolism with biliary excretion (about 40% as unchanged drug and metabolites in bile). Renal excretion accounts for approximately 8-15% of the dose as unchanged drug and metabolites. Fecal elimination is less than 20%.
Parent drug: 94-97% bound, primarily to albumin. Idarubicinol (active metabolite): ~95% bound to albumin.
Approximately 50-70% bound to plasma proteins, primarily albumin.
Vd: 20-30 L/kg (mean ~25 L/kg). Very large distribution indicates extensive tissue binding and penetration into cells, particularly in bone marrow.
Volume of distribution is high, ranging from 15-30 L/kg, indicating extensive tissue binding and distribution, particularly into erythrocytes and tissues.
Oral bioavailability: approximately 28% (range 10-40%) due to first-pass metabolism. Not available orally in typical clinical practice; IV administration is standard. Oral formulations exist for investigational use but not FDA-approved.
Oral bioavailability is less than 5% due to extensive first-pass metabolism; therefore, not administered orally. IV administration results in 100% bioavailability.
If serum creatinine > 2 mg/d L or creatinine clearance < 30 m L/min, reduce dose by 25-50% and monitor cardiac function.
Cr Cl 10–50 m L/min: reduce dose by 25%; Cr Cl <10 m L/min: reduce dose by 50%. Hemodialysis: administer after dialysis; dose reduction by 50%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or consider alternative therapy.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
10-12 mg/m² IV daily for 3 days; maximum cumulative dose 600 mg/m²; adjust for renal/hepatic impairment.
25–45 mg/m² IV on days 1–3 every 21 days; neonates: <10 kg: 1 mg/kg IV daily for 3–5 days.
Start at lower end of dosing range (e.g., 10-12 mg/m²), monitor cardiac function closely due to increased risk of cardiomyopathy; reduce dose for renal impairment.
Initiate at lower end of dose range (30 mg/m²/day for 3 days) due to increased myelotoxicity; monitor renal function.
Idarubicin should be administered only under the supervision of physicians experienced in leukemia chemotherapy. Severe myelosuppression occurs. Cardiotoxicity (including heart failure, arrhythmias, and cardiomyopathy) may occur, especially with cumulative doses exceeding 150 mg/m². Extravasation can cause severe tissue necrosis. Reduction of left ventricular ejection fraction (LVEF) and congestive heart failure have been reported.
Severe myelosuppression; cumulative dose-related cardiotoxicity; extravasation with tissue necrosis; secondary leukemias.
Myelosuppression: severe bone marrow suppression leading to infection, bleeding, and anemia,Cardiotoxicity: acute (arrhythmias, myocardial depression) and chronic (cumulative dose-related cardiomyopathy); monitor LVEF,Secondary malignancies: higher risk of therapy-related myelodysplasia or acute leukemia,Extravasation: severe tissue damage if extravasation occurs; use central line administration,Tumor lysis syndrome: rapid lysis of tumor cells can cause uric acid nephropathy,Hepatic impairment: requires dose reduction,Renal impairment: requires dose reduction,Immunosuppression: live vaccines contraindicated
Bone marrow suppression; cardiac toxicity (cumulative doses >550 mg/m²); hepatic and renal impairment; tumor lysis syndrome; immunosuppression.
Hypersensitivity to idarubicin or any component of the formulation,Severe hepatic impairment (bilirubin >5 mg/d L),Severe renal impairment (creatinine clearance <15 m L/min),Inadequate bone marrow reserve due to prior chemotherapy or radiotherapy,Pregnancy (category D): can cause fetal harm,Lactation: discontinue nursing or drug
Severe myelosuppression; previous anthracycline therapy at maximum cumulative dose; severe hepatic impairment; severe cardiac disease; pregnancy.
Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism and increase idarubicin toxicity. No other significant food interactions are reported. Maintain adequate hydration to prevent tumor lysis syndrome; avoid alcohol as it may exacerbate hepatic toxicity.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition increasing toxicity. No other specific food restrictions reported.
Pregnancy category D. First trimester: high risk of fetal malformations (central nervous system, cardiovascular, skeletal). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal myelosuppression. Avoid use unless maternal benefit outweighs risks.
Pregnancy Category D. First trimester: High risk of congenital malformations including craniofacial, skeletal, CNS, and cardiac defects. Second and third trimesters: Risk of fetal growth restriction, prematurity, and neonatal myelosuppression.
Not recommended. Idarubicin is excreted into breast milk; M/P ratio not available. Potential for severe adverse effects in nursing infant including neutropenia and cardiotoxicity.
Contraindicated during breastfeeding. Daunorubicin is excreted into breast milk; M/P ratio unknown due to limited data. Potential for severe adverse effects in nursing infant including immunosuppression, cardiotoxicity, and carcinogenesis.
No established dose adjustments in pregnancy. Pharmacokinetic changes (increased volume of distribution, altered clearance) may require dose individualization based on BSA and toxicity monitoring. Use lowest effective dose with aggressive supportive care.
No established dosing adjustments for pregnancy. Standard dosing based on body surface area, but use only if clearly needed due to teratogenicity. Increased volume of distribution may alter pharmacokinetics, but formal dose modifications not defined.
Idarubicin is a potent anthracycline with significant cardiotoxicity; cumulative lifetime dose should not exceed 150 mg/m² in adults. Administer IV slowly over 5-10 minutes to reduce risk of extravasation, which causes severe tissue necrosis. Monitor for acute infusion reactions and premedicate with antiemetics. Renal and hepatic impairment require dose adjustment; check bilirubin and creatinine levels before each cycle. Concomitant use with other cardiotoxic agents increases risk of heart failure.
Cerubidine (daunorubicin) is an anthracycline antineoplastic antibiotic; premedicate with antiemetics; monitor for cardiotoxicity (cumulative dose limit 550 mg/m², or 450 mg/m² with prior chest radiation); administer via IV over 15-30 minutes to avoid extravasation (vesicant); observe for rapid lysis syndrome in high-tumor-burden patients; adjust dose for hepatic impairment (bilirubin >1.2 mg/d L).
Tell your doctor if you have heart, liver, or kidney problems before starting treatment.,You will need regular blood tests to monitor blood counts and heart function.,Report any chest pain, shortness of breath, or swelling in your ankles immediately.,Avoid grapefruit and grapefruit juice during treatment as it may increase side effects.,Use effective contraception during and for at least 6 months after treatment.,Notify your healthcare provider if you experience fever, chills, or signs of infection.,This medication may cause your urine to turn reddish-orange for 1-2 days after administration.
This drug may cause irreversible heart damage at high cumulative doses; report chest pain, shortness of breath, or swelling of ankles/feet.,You will need regular blood tests to monitor blood cell counts and heart function.,Notify your healthcare provider immediately if you experience pain, redness, or swelling at the injection site.,This medication can cause severe nausea and vomiting; antiemetic therapy will be given.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception; do not breastfeed while on this medication.,Your urine may appear reddish-orange for 1-2 days after treatment; this is harmless.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IDAMYCIN vs CERUBIDINE, answered by our medical review team.
IDAMYCIN is a Anthracycline Antineoplastic that works by Idarubicin is an anthracycline antineoplastic agent that intercalates with DNA and inhibits topoisomerase II, leading to inhibition of DNA replication and transcription, and ultimately cell death. It also generates free radicals and induces apoptosis.. CERUBIDINE is a Anthracycline antineoplastic that works by Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II and preventing DNA replication and transcription, leading to cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IDAMYCIN and CERUBIDINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IDAMYCIN is: 12 mg/m² IV daily for 3 days (acute myeloid leukemia) or 12 mg/m² IV daily for 3 days (acute lymphoblastic leukemia); maximum cumulative dose 600 mg/m².. The standard adult dose of CERUBIDINE is: 45–60 mg/m² IV on days 1–3 every 21–28 days, or 30–60 mg/m² IV daily for 3 days every 3 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IDAMYCIN and CERUBIDINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IDAMYCIN is classified as Category C. Pregnancy category D. First trimester: high risk of fetal malformations (central nervous system, cardiovascular, skeletal). Second and third trimesters: increased risk of fetal gro. CERUBIDINE is classified as Category C. Pregnancy Category D. First trimester: High risk of congenital malformations including craniofacial, skeletal, CNS, and cardiac defects. Second and third trimesters: Risk of fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.